Miyazaki M, Bai L, Tsuboi S, Namba M
Department of Cell Biology, Okayama University Medical School, Japan.
J Cancer Res Clin Oncol. 1992;118(6):435-40. doi: 10.1007/BF01629426.
The effects of four barbiturates with or without liver-tumor-promoting activity were examined on survival and deoxyribonucleic acid (DNA) synthesis of suckling and adult rat hepatocytes in serum-free primary culture: Of the four barbiturates, two promoters, phenobarbital and barbital, enhanced DNA synthesis of suckling rat hepatocytes at low concentrations of 0.5-2 mM or 0.5 mM, but suppressed it at high concentrations of 3 mM or 1.5-4 mM. DNA synthesis of adult rat hepatocytes was, however, only suppressed by phenobarbital within the dose range tested of 1-3 mM. On the other hand, two remaining non-promoters, barbituric acid and amobarbital, did not increase but only suppressed DNA synthesis of suckling rat hepatocytes within the dose ranges of 0.5-4 mM and 0.05-0.5 mM respectively. Phenobarbital and amobarbital were effective for supporting survival and maintaining morphological features of suckling and adult rat hepatocytes at the relatively high concentrations of 3-4 mM and 0.5-0.75 mM respectively. However, barbital and barbituric acid were ineffective for maintenance of hepatocytes. The results show that the ability to support survival of primary cultured hepatocytes is not a common property of liver-tumor-promoter barbiturates but is a common property of some barbiturates with high lipophilicity, and that the maintenance of hepatocytes by phenobarbital or amobarbital is not due to a counterbalance of stimulated proliferation and death of the cells.
研究了四种具有或不具有肝肿瘤促进活性的巴比妥类药物对无血清原代培养的乳鼠和成年大鼠肝细胞存活及脱氧核糖核酸(DNA)合成的影响:在这四种巴比妥类药物中,两种促癌剂苯巴比妥和巴比妥,在低浓度0.5 - 2 mM或0.5 mM时增强了乳鼠肝细胞的DNA合成,但在高浓度3 mM或1.5 - 4 mM时则抑制了DNA合成。然而,在1 - 3 mM的测试剂量范围内,成年大鼠肝细胞的DNA合成仅被苯巴比妥抑制。另一方面,其余两种非促癌剂巴比妥酸和异戊巴比妥,在分别为0.5 - 4 mM和0.05 - 0.5 mM的剂量范围内,并未增加而是仅抑制了乳鼠肝细胞的DNA合成。苯巴比妥和异戊巴比妥分别在相对较高的浓度3 - 4 mM和0.5 - 0.75 mM时,对支持乳鼠和成年大鼠肝细胞的存活及维持其形态特征有效。然而,巴比妥和巴比妥酸对肝细胞的维持无效。结果表明,支持原代培养肝细胞存活的能力并非肝肿瘤促癌剂巴比妥类药物的共同特性,而是一些高亲脂性巴比妥类药物的共同特性,并且苯巴比妥或异戊巴比妥对肝细胞的维持并非由于细胞增殖刺激与死亡的平衡。